MTNB (Matinas BioPharma Holdings, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MTNB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | ADAM K STERN | 10%+ Owner | X | — | — |
| 2026-08-13 | Sanitam Partners LLC | 10%+ Owner | J | — | — |
| 2025-05-02 | An Evelyn D | Director | A | — | — |
| 2025-05-02 | EDWARD NEUGEBOREN | Director | A | — | — |
| 2025-05-02 | Jerome D Jabbour | President and CEO | A | — | — |
| 2025-05-02 | Robin L Smith | Director | A | — | — |
| 2025-05-02 | Keith Murphy | Director | A | — | — |
| 2025-04-10 | Sanitam Partners LLC | 10%+ Owner | Buy | — | — |
| 2025-04-10 | ROBERT J EIDE | 10%+ Owner | Buy | — | — |
| 2025-04-10 | Pembroke & Partners LLC | 10%+ Owner | Buy | — | — |
| 2023-12-15 | Hui Liu | Chief Technology Officer | A | — | — |
| 2023-12-15 | Keith A Kucinski | Chief Financial Officer | A | — | — |
| 2023-12-15 | James J. Ferguson III | Chief Medical Officer | A | — | — |
| 2023-12-15 | Jerome D Jabbour | President and CEO | A | — | — |
| 2023-12-15 | Theresa Matkovits | Chief Development Officer | A | — | — |
| 2023-12-15 | Thomas Hoover | Chief Business Officer | A | — | — |
| 2023-11-03 | Eric J Ende | Director | A | — | — |
| 2023-11-03 | Natasha Giordano | Director | A | — | — |
| 2023-11-03 | MATTHEW WIKLER | Director | A | — | — |
| 2023-11-03 | HERBERT J CONRAD | Director | A | — | — |
| 2023-11-03 | Kathryn Penkus Corzo | Director | A | — | — |
| 2023-11-03 | James S Scibetta | Director | A | — | — |
| 2022-12-22 | Jerome D Jabbour | President and CEO | A | — | — |
| 2022-12-22 | Thomas Hoover | Chief Business Officer | A | — | — |
| 2022-12-22 | Hui Liu | Chief Technology Officer | A | — | — |
| 2022-12-22 | Keith A Kucinski | Chief Financial Officer | A | — | — |
| 2022-12-22 | James J. Ferguson III | Chief Medical Officer | A | — | — |
| 2022-12-22 | Theresa Matkovits | Chief Development Officer | A | — | — |
| 2022-11-16 | Eric J Ende | Director | A | — | — |
| 2022-11-16 | Natasha Giordano | Director | A | — | — |
| 2022-11-16 | Kathryn Penkus Corzo | Director | A | — | — |
| 2022-11-16 | James S Scibetta | Director | A | — | — |
| 2022-11-16 | MATTHEW WIKLER | Director | A | — | — |
| 2022-11-16 | HERBERT J CONRAD | Director | A | — | — |
| 2022-07-05 | HERBERT J CONRAD | Director | G | — | — |
| 2022-01-03 | MATTHEW WIKLER | Director | A | — | — |
| 2021-12-15 | Theresa Matkovits | Chief Development Officer | A | — | — |
| 2021-12-15 | Keith A Kucinski | Chief Financial Officer | A | — | — |
| 2021-12-15 | RAPHAEL J MANNINO | Chief Scientific Officer | A | — | — |
| 2021-12-15 | Liu Hui | Chief Technology Officer | A | — | — |
| 2021-12-15 | Jerome D Jabbour | President and CEO | A | — | — |
| 2021-12-15 | Thomas Hoover | Chief Business Officer | A | — | — |
| 2021-12-15 | James J. Ferguson III | Chief Medical Officer | A | — | — |
| 2021-11-02 | HERBERT J CONRAD | Director | A | — | — |
| 2021-11-02 | MATTHEW WIKLER | Director | A | — | — |
| 2021-11-02 | Kathryn Penkus Corzo | Director | A | — | — |
| 2021-11-02 | Natasha Giordano | Director | A | — | — |
| 2021-11-02 | James S Scibetta | Director | A | — | — |
| 2021-11-02 | Eric J Ende | Director | A | — | — |
| 2021-10-01 | MATTHEW WIKLER | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 70,788 | — |
| — | Director | 66,729 | — |
| — | 10%+ Owner | 41,732 | — |
| — | Chief Scientific Officer | 38,394 | — |
| — | Director | 34,260 | — |
| — | President and CEO | 16,800 | — |
| — | Director | 12,519 | — |
| — | Director | 11,111 | — |
| — | Director | 8,000 | — |
| — | Director | 5,809 | — |
| — | Director | 2,402 | — |
| — | 10%+ Owner | 1,500 | — |
| — | Chief Financial Officer | 730 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MTNB quote page; the site-wide leaderboard is on the insider transactions hub.